The ribosomal acidic P0 protein, an essential component of the eukaryotic ribosomal stalk, was found to interact with the helix-loop-helix protein human Grap2 and cyclin D interacting protein (GCIP)/D-type cyclin-interacting protein 1/human homolog of MAID protein. Using in vivo and in vitro binding assays, we show that P0 can interact with the N and C termini of GCIP via its N-terminal 39-114 amino-acid residues. Although the P0-GCIP complex was detected mainly in cytoplasmic fraction, polysome profile analysis indicated that the P0-GCIP complex did not coelute with either polysomes or 60S ribosomes, suggesting that GCIP associates with the free form of P0 in the cytoplasm. Transfection of GCIP into MCF-7 cells resulted in decreased levels of pRb phosphorylation. Cotransfection of P0 with GCIP, however, resulted in GCIP-mediated reduction of pRb phosphorylation level which was repressed by P0. Furthermore, overexpression of P0 in breast cancer and hepatocellular cancer cell lines promoted cell growth and colony formation compared to control transfectants. Overexpression of P0 also increased cyclin D1 expression and phosphorylation of pRb at Ser780. Interestingly, P0 mRNA was overexpressed in 12 of 20 pairs of breast cancer/ normal breast specimens (60%). Together, these data indicate that P0 overexpression may cause tumorigenesis in breast and liver tissues at least in part by inhibiting GCIP-mediated tumor suppression.
Introduction
Ribosomal phosphoprotein P0, together with heterodimers of the two other acidic phosphoproteins, P1 and P2, forms the pentamer, P0 (P1-P2) 2 , which is located in the active part of the ribosome particle. Within the active part of the ribosome, mRNAs, tRNAs and translation factors interact with each other during protein synthesis (Wool et al., 1991) . However, P1 and P2 proteins are not absolutely required for this function, as translation can continue at a slow rate in yeast deletion mutants lacking P1 and P2 proteins. Conversely, P0 seems to be essential and in its absence, deficient 60S ribosomal subunits are assembled that are inactive in protein synthesis and lead to cell lethality (Remacha et al., 1995) .
Increased expression of human P0 has been reported in cells with defective O 6 -methylguanine methyltransferase (Mer À ) (Grabowski et al., 1992) as well as in the cells of human colon and hepatocellular carcinomas (HCCs) (Barnard et al., 1992; Kondoh et al., 1999) . These findings suggest that although human P0 protein is the central component of the stalk and essential for the ribosome activity, it is also involved in other cellular functions such as tumorigenesis.
Therefore, it is of interest to search for additional proteins that might interact with P0 and to observe the effect of overexpressing P0 on the malignant phenotype of cancer cell lines. This study presents results that demonstrate a physical interaction between P0 and a novel protein, GCIP, a human Grap2 and Cyclin D Interacting Protein (Xia et al., 2000) , which is also recognized as a human homolog of MAID protein (HHM) (Terai et al., 2000) and a D-type cyclininteracting protein 1 (DIP1) (Yao et al., 2000) . We further show here that increased expression of P0 in cells could execute its oncogenic activity by inhibiting GCIPmediated reduction of Rb phosphorylation and enhance the expression of cyclin D1.
Results

Identification of GCIP as a P0-binding protein
We screened the human mammary gland cDNA library using the full-length P0 cDNA as bait in a yeast twohybrid interaction trap and identified GCIP as a potential interactor for P0. The GCIP protein was found to be expressed in various cell types and in most human tissues with the highest level of expression in the heart, muscle, peripheral blood leukocytes and brain (Xia et al., 2000) .
To examine whether GCIP is able to interact with P0 in mammalian cells, a vector containing P0 was transfected into human 293T cells, and then immunoblot analysis was performed. The results showed that c-Myc-P0 were specifically coimmunoprecipitated by anti-GCIP antibody (Figure 1a) . To determine whether this interaction also occurs with endogenous P0 and GCIP proteins, coimmunoprecipitation assays with 293T cells and with human MCF-7 cells were carried out. The results revealed that endogenous GCIP protein was specifically coimmunoprecipitated by anti-P0 antibody and endogenous P0 protein was specifically coimmunoprecipitated by anti-GCIP antibody but not by preimmune sera in both 293T cells (Figure 1b ) and MCF-7 cells (Figure 1c ), providing further evidence that the P0-GCIP interaction occurs in the presence of physiological protein levels.
Free form of ribosomal protein P0 is associated with GCIP in cytoplasmic fraction of cells To determine where the P0-GCIP binding may occur in cells, cell lysates from 293T cells cotransfected with c-Myc-P0/Flag-GCIP were fractionated into cytoplasmic and nuclear fractions, and immunoblotting was performed. The results indicated that the c-Myc-P0-Flag-GCIP complex was present mainly in the cytoplasm (Supplementary Figure 1A) . To investigate further whether c-Myc-P0 and Flag-GCIP also co-localizes in the cytoplasm of MCF-7 cells or not, MCF-7 cells transfected with either c-Myc-P0 or Flag-GCIP and cotransfected with c-Myc-P0/Flag-GCIP were subjected to immunofluorescent staining. Consistent with the previous reports (Yao et al., 2000; Tchorzewski et al., 2003) , c-Myc-P0 transfectants showed a ubiquitous cytoplasmic fluorescence and Flag-GCIP transfectants showed fluorescence almost exclusively in the nucleus P0 interacts with GCIP and P0 associated with proliferation T-W Chang et al ( Figure 2A ). However, cotransfection of c-Myc-P0 with Flag-GCIP resulted in a significant increase in Flag-GCIP cytoplasmic fraction (compare Figure 2Ac and Figure 2Bb ) and co-localization with c-Myc-P0 (Figure 2Bc ). In addition, cotransfection of c-Myc-P0 113-317 (P0 113-317 is a truncated P0 that lacks the interaction site with GCIP, see below) with Flag-GCIP did not affect the subcellular localization of GCIP ( Figure 2Bf ) and there was no overlapping of the Flag-GCIP and c-Myc-P0 113-317 fluorescence signals ( Figure  2Bg ), suggesting that the Flag-GCIP redistribution from the nucleus to the cytoplasm is specifically mediated by the GCIP-binding region of P0.
To investigate whether cytoplasmic GCIP interacts in vivo with free form of P0 or with P0 associated with the ribosomal subunit, the sedimentation profile of cytoplasmic extracts from 293T cells cotransfected with c-Myc-P0/Flag-GCIP was analysed. The results indicated that P0 sediments in both the cytosolic ribosomefree and ribosome fractions, while GCIP sediments in the cytosolic ribosome-free fraction, suggesting that cytoplasmic GCIP interacts with the free cytosolic ribosomal protein P0 (Supplementary Figure 1B) .
Mapping the binding domains of P0 and GCIP
To map the interaction domains of P0 and GCIP, we tested individual domains as well as serial deletions from P0 against full-length GCIP target and vice versa using pull-down assays. Our results indicated that the Nterminal 39-114 amino-acid residues of P0 exhibited strong binding to GCIP, whereas both the N (1-190 amino-acid residues) and C-terminal (240-360 aminoacid residues) regions of GCIP have a P0-binding capacity (Supplementary Figure 2) .
GCIP-mediated inhibition of pRb phosphorylation was repressed by P0
To determine whether the interaction between P0 and GCIP has any effect on the phosphorylation of pRb protein, cotransfection experiments with ppRb-TA-Luc were performed in MCF-7 cells. As shown in Figure 3 , reporter activity decreased in cells cotransfected with a plasmid expressing GCIP but not with a plasmid expressing P0. This result indicated that GCIP, but not P0, has an inhibitory effect on the phosphorylation of pRb. In contrast, cotransfection of P0 with GCIP resulted in downregulation of the reporter activity was relieved by P0 in a dose-dependent manner. These results indicated that GCIP-mediated inhibition of pRb phosphorylation is repressed by P0. This repression was specific for the presence of a GCIP-binding region in the P0 interacts with GCIP and P0 associated with proliferation T-W Chang et al P0 N terminus, because cotransfection of P0 1-114 had a similar effect on reporter activity as those of intact P0 and cotransfection of P0 113-317 had no effect on reporter activity (Figure 3 ). Figures 3c and d) .
Whether the c-Myc-P0-overexpressing cells affected the anchorage-independent growth potential of parental cells was also examined and the results indicated that P0-M3 cells exhibited a statistically significant increase in the number of colonies compared with its empty vector-transfected cells, whereas P0-M3-siRNA cells exhibited a significant reduction in the number of colonies compared with P0-M3-mock cells (Supplementary Figure 4) . Similarly, P0-H1 cells also showed a statistically significant increase in the number of colonies compared with its empty vector-transfected cells (data not shown).
P0-overexpressing cells exhibit increased cyclin D1 expression and the phosphorylation of pRb at Ser780
Since GCIP could inhibit the expression of cyclin D1 protein in the cells (Ma et al., 2006) , we also examined whether overexpression of P0 could enhance the expression of cyclin D1 protein in the cells. As shown in Figure 4 , western blot analysis revealed that the expression level of cyclin D1 increased. Furthermore, the results also revealed an increase in phosphorylation of pRb at Ser780, a site targeted exclusively by cyclin D1-Cdk4 (Kitagawa et al., 1996) , in P0-M3 and P0-M1 cells (Figure 4a ) as well as P0-H1 and P0-H2 cells (Figure 4b ) when compared to their respective empty vector-transfected cells. However, there was no apparent change in the protein levels of pRb in all the cell lines examined (Figure 4) . These results suggested that P0 is able to promote tumorigenesis by inhibiting GCIP-mediated regulation of expression, and therefore function, of cyclin D1.
Higher expression level of P0 in cancerous breast tissues than that in the normal breast tissues The mRNA levels of the P0 in 20 pairs of both cancerous and normal breast tissues were compared by competitive RT-PCR. In eight pairs, there was no Figure 3 GCIP-mediated inhibition of pRb phosphorylation is repressed by P0. MCF-7 cells were transiently cotransfected with ppRb-TA-Luc, together with either a pMH, pMH-P0, pMH-P0 1-114 , pMH-P0 113-317 , pMH-GCIP, or a combination of two plasmids (as indicated beneath each column). The luciferase activity when 2 mg of pMH was transfected was set as 100%. The introduction of intact P0 or P0 1-114 but not truncated P0 113-317 efficiently suppressed the GCIP-mediated inhibition of pRb phosphorylation. Statistical significance was calculated by comparing pMH to experimental data. *Mean Po0.005; ***mean Po0.001. GCIP, human Grap2 and cyclin D interacting protein.
P0 interacts with GCIP and P0 associated with proliferation T-W Chang et al difference in P0 mRNA levels between the cancerous and normal breast tissues. In contrast, the levels of P0 mRNA in the remaining 12 cancerous breast tissues were found to be higher than those in normal breast tissues. Interestingly, none of the cancerous samples showed significantly higher levels of ribosomal protein P1 mRNA expression when compared to the normal tissues. Some of the results are shown in Supplementary  Figure 5 .
Discussion
Previous studies have suggested that GCIP acts as a potential tumor suppressor in human cancers, especially in breast and liver carcinoma cells. First, Takami et al. (2005) reported that expression of GCIP was high in the early (well differentiated) HCC but relatively low in the more progressive (poorly differentiated) HCC samples, indicating that the decrease of GCIP might be a prerequisite event for further tumor progression. Second, Sonnenberg-Riethmacher et al. (2007) reported that lack of Maid (GCIP) promotes the occurrence of HCCs in older mice, suggesting the absence of GCIP can contribute to a higher tumor incidence in the liver. Third, Ma et al. (2006) showed that overexpression of GCIP in mouse liver suppressed diethylnitrosamineinduced liver tumors in transgenic mice at an early stage of tumor development. Importantly, their studies suggest that GCIP might be a tumor suppressor protein. Furthermore, Yao et al. (2000) have shown that stable overexpression of DIP (GCIP) in MCF-7 cells markedly inhibits growth. Consistent with our findings report here, Ma et al. (2007) have shown that overexpression of GCIP in SW480 colon cancer line resulted in a significant inhibition on tumor cell colony formation.
It is well known that the C-terminal 120 amino-acid residues of P0 is responsible for the interaction with elongation factor EF-2 and P1/P2 proteins (Uchiumi and Kominami, 1997) , whereas an arginine-rich region (residues 44-67 in the rat protein) in the N-terminal half of P0 has been found to be responsible for binding of the pentamer to RNA (Shimizu et al., 2002) . This argininerich region is 100% conserved among the frog, rat, chicken and human proteins (Wu and Storey, 2005) . Since our results showed that P0 interacts with GCIP through amino acids 39-114, which also contain the arginine-rich RNA-binding region, and since GCIP interacts with the free form of P0, it raises the possibility that GCIP and RNA could compete for binding with P0 in the cytoplasm. Although GCIP itself does not contain a consensus nuclear localization signal (NLS) sequence, a previous study reported that GCIP could associate with a nuclear protein p29, which may contribute GCIP to be localized in the nucleus and to execute its function in the nucleus (Chang et al., 2000) . Thus, the formation of cytoplasmic complex of P0-GCIP may sequester GCIP in the cytoplasm, which results in inhibiting the GCIP-mediated reduction of pRb phosphorylation, thereby accelerating cell growth. However, coexpression of c-Myc-P0 with Flag-GCIP in 293T and MCF-7 cells partially retained Flag-GCIP in the cytoplasm and some of Flag-GCIP still remained in the nucleus (Supplementary Figure 1Aa and Figure 2Bb) . At this point, we cannot exclude that P0 could promote cell proliferation through additional mechanisms that do not involve the ability to repress GCIP activity.
Genetic aberrations in the regulatory circuits that govern the G 1 -S phase transition occur frequently in human cancer, and overexpression of cyclin D1 is one of the most commonly observed alterations (Diehl, 2002) . Of notable importance is that the cyclin D1 gene is amplified in a number of primary cancers including hepatomas and breast cancers. The cyclin D1 protein overexpression, however, has been detected at a higher frequency than can be accounted for by gene amplification alone (Hosokawa and Arnold, 1996) . Thus, mechanisms other than DNA amplification may contribute to maintaining cyclin D1 overexpression. The Figure 4 P0-overexpressing cells exhibit increased cyclin D1 and pRb S780 . Cell lysates from (a) P0-M3, P0-M1 and pc-9 (MCF-7-derivative transfectants) and from (b) P0-H1, P0-H2 and pc-8 (Hep-G2-derivative transfectants) were separated by SDS-PAGE following immunoblotting using anti-pRb, -pRb S780 , anti-cyclin D1, anti-c-Myc and anti-a-tubulin antibodies. The data show that P0-overexpressing cells, P0-M3, P0-M1, P0-H1 and P0-H2, exhibited an increase in cyclin D1 and pRb S780 protein levels when compared to their empty vector-transfected cells. In contrast, there was no apparent change in the protein levels of pRb in these transfected cells.
P0 interacts with GCIP and P0 associated with proliferation T-W Chang et al increased expression of P0 was found in HCCs and colorectal cancers, and in this study, we also showed that the levels of P0 mRNA in 12 of the 20 breast cancerous tissues are higher than those in the normal breast tissues. In addition, the present study also revealed that overexpression of P0 is able to enhance the expression of cyclin D1 protein by inhibiting GCIPmediated reduction of pRb phosphorylation in transfected cells. In light of these findings, and the fact that GCIP is a ubiquitously expressed in mammalian tissues, it is intriguing to speculate that the enhancement of P0 might be an important factor that is responsible for, or contribute to, the overexpression of cyclin D1 in various primary cancers, particularly in the colon, liver and breast carcinomas. Biosynthesis of all ribosomal components is strictly coordinated with the changes in cellular growth in normal cells. Since P0 and P1 directly interact with each other to form ribosomal stalk, it is thought that normal cells may maintain a constant molar ratio of P0 to P1. Since free form of ribosomal protein P0, which resulted from the relative abundance of P0, has a more specific role in regulating proliferation through its interaction with GCIP than simply influencing the rate of protein biogenesis, some tumor cells might evolve mechanisms for specifically overexpressing P0 to gain growth or survival advantages. Our findings that P0, but not P1, was overexpressed in some breast cancerous tissues and experimental overexpression of P0 could promote proliferation in breast and liver cancerous cells are consistent with this notion.
In summary, our data clearly demonstrated that besides its major role to form a ribosomal stalk, P0 can also interact with GCIP, a ubiquitously expressed protein in mammalian tissues. P0 could accelerate cell growth when it was overexpressed in the human breast and liver cancerous cells. This increase of cell proliferation is apparently due to the presence of increased levels of free form P0, which executed its tumorigenetic function at least in part by inhibiting GCIP-mediated reduction of pRb phosphorylation and enhancing the expression of cyclin D1 protein rather than simply executing its involvement in ribosomal function.
Materials and methods
Cell lines and antibodies MCF-7, HEK-293T and Hep-G2 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Antibodies for immunoprecipitation or western blotting were as follows: anti-Flag (Sigma, SigmaAldrich, St Louis, MO, USA); anti-cyclin D1 (Sigma); antic-Myc (Clontech, Mountain View, CA, USA); anti-pRb (Santa Cruz Biotechnology, Santa Cruz, CA, USA); anti-pRb S780 (pRb phosphorylated on Ser780) (Cell Signaling Technology, Danvers, MA, USA); anti-a-tubulin (Neomarker, Fremont, CA, USA); and anti-Lamin B (Zymed Laboratories, San Francisco, CA, USA). The HRP-conjugated goat anti-mouse and anti-rabbit secondary antibodies were purchased from Chemicon (Temecula, CA, USA).
Plasmid constructs and antibody productions
To generate c-Myc-tagged P0 and Flag-tagged GCIP expression plasmids, the cDNAs for full-length P0 and GCIP were amplified by PCR and inserted into pcDNA3.1B (Invitrogen, Paisely, UK) and p3X-Flag (Sigma) to generate pcDNA3.1B-P0 and p3X-Flag-GCIP plasmids, respectively.
For anti-P0 and anti-GCIP antibodies production, the cDNA for full-length P0 and GCIP were inserted into pGEX-5X (Amersham Pharmacia, Piscataway, NJ, USA). The recombinant fusion proteins were expressed, induced in 0.5 mM isopropyl-b-D-thiogalactopyranoside in Escherichia coli BL21 (DE3), and were purified with glutathione-Sepharose 4B beads (Amersham Pharmacia) and then used to produce polyclonal antiserum in rabbits.
Western blotting and immunoprecipitation
For western blotting analyses, cells were washed with cold phosphate-buffered saline (PBS) and lysed in EBC250 lysis buffer (50 mM Tris-HCl (pH 8.0), 250 mM NaCl, 1 mM phenylmethylsulphonyl fluoride, 1% Nonidet P-40, 2 mg/ml leupeptin and 2 mg/ml aprotinin). Equal amounts of protein (50 mg) were separated by 10-12% sodium dodecyl sulfatepolyacrylamide gel (SDS-PAGE) and transferred to PVDF membrane (Millipore, Bedford, MA, USA). The membranes were blocked with TBST buffer containing 5% non-fat milk, and incubated with indicated primary antibody. The membranes were then incubated with HRP-conjugated secondary antibodies and were visualized using the ECL chemiluminescent method (Amersham Pharmacia).
For IP-western analyses, cells that were transfected with plasmids, were washed with cold PBS and lysed in EBC150 buffer (same as EBC250 except 150 mM NaCl). Then 500 mg of cell lysates were incubated with 2-5 mg of the indicated antibodies for 10-14 h at 41C. Fifty microliters of protein Aagarose (Amersham Pharmacia) was added and incubated; the immunocomplexes were resolved by SDS-PAGE followed by western blotting.
Immunofluorescence MCF-7 cells were transfected with plasmids using Lipofectamine 2000 (Invitrogen). After 48 h, cells were fixed with 3.7% formaldehyde in PBS buffer, and permeabilized with 0.2% Triton X-100, and blocked in PBS containing 5% bovine serum albumin. Primary antibodies used were rabbit anti-Myc (1:200) (Sigma) and mouse anti-Flag (1:200). The secondary antibodies used were anti-rabbit Alexa 594 (1:500) and antimouse Alexa 488 (1:500) (Molecular Probes, Carlsbad, CA, USA). The nuclei were stained with 4 0 ,6 0 -diamidino-2-phenylindole (DAPI, Molecular Probes). Images were captured with the Olympus fluorescence microscope with attached CCD camera at Â 100 magnification.
pRb phosphorylation reporter assays To examine the influence of P0 and/or GCIP on pRb activity, the reporter plasmid, ppRb-TA-Luc (Clontech), which contained a luciferase gene under the control of a phosphorylated form of pRb-responsive element, was used. The full-length P0 expression plasmid pMH-P0, and the truncated P0 expression plasmids, pMH-P0 113-317 and pMH-P0 1-114 , were amplified by PCR and subcloned into pMH (Roche, Molecular Biochemicals, Palo Alto, CA, USA), respectively. The full-length GCIP expression plasmid, pMH-GCIP, was constructed by amplifying the cDNA and inserted into pMH. For pRb phosphorylation reporter assays, 5 Â 10 5 MCF-7 cells were transiently transfected with either pMH, pMH-P0, pMH-P0 1-114 , pMH-P0 113-317 , pMH-GCIP or a combination of both expression plasmids (pMH-GCIP plus pMH-P0, pMH-P0 1-114 or pMH-P0 113-317 ) together with 0.5 mg of ppRb-TA-Luc and 0.5 mg of pSV-b-galactosidase plasmid (Promega, Madison, WI, USA) using Lipofectamine 2000. After 24 h, the cells were lysed, and luciferase activity and b-galactosidase activity were determined following the manufacturer's instructions (Promega). Luciferase activity is given as mean7s.d. of triplicated transfection, each conducted in duplicate.
Statistical analysis
Data were analysed using SigmaPlot to determine P-value (t-test).
